| Literature DB >> 34166225 |
Yizhen Li1, Wentao Yang1, Meenakshi Devidas2, Stuart S Winter3, Chimene Kesserwan4, Wenjian Yang1, Kimberly P Dunsmore5, Colton Smith1, Maoxiang Qian6, Xujie Zhao1, Ranran Zhang7, Julie M Gastier-Foster8, Elizabeth A Raetz9, William L Carroll9, Chunliang Li10, Paul P Liu11, Karen R Rabin12, Takaomi Sanda13, Charles G Mullighan14, Kim E Nichols15, William E Evans1, Ching-Hon Pui15, Stephen P Hunger16, David T Teachey17, Mary V Relling1, Mignon L Loh18, Jun J Yang1.
Abstract
Genetic alterations in the RUNX1 gene are associated with benign and malignant blood disorders, particularly of megakaryocyte and myeloid lineages. The role of RUNX1 in acute lymphoblastic leukemia (ALL) is less clear, particularly how germline genetic variation influences the predisposition to this type of leukemia. Sequencing 4,836 children with B-ALL and 1,354 cases of T-ALL, we identified 31 and 18 germline RUNX1 variants, respectively. RUNX1 variants in B-ALL consistently showed minimal damaging effects. By contrast, 6 T-ALL-related variants result in drastic loss of RUNX1 activity as a transcription activator in vitro. Ectopic expression of dominant-negative RUNX1 variants in human CD34+ cells repressed differentiation into erythroid, megakaryocytes, and T cells, while promoting myeloid cell development. Chromatin immunoprecipitation sequencing of T-ALL models showed distinctive patterns of RUNX1 binding by variant proteins. Further whole genome sequencing identified JAK3 mutation as the most frequent somatic genomic abnormality in T-ALL with germline RUNX1 variants. Co-introduction of RUNX1 variant and JAK3 mutation in hematopoietic stem and progenitor cells in mice gave rise to T-ALL with early T-cell precursor phenotype. Taken together, these results indicated that RUNX1 is an important predisposition gene for T-ALL and pointed to novel biology of RUNX1-mediated leukemogenesis in the lymphoid lineages.Entities:
Keywords: Genetic variation; Genetics; Leukemias; Oncology
Year: 2021 PMID: 34166225 PMCID: PMC8409579 DOI: 10.1172/JCI147898
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808